CSIMarket Company Name, Ticker, Customers, else..
 
Cervomed Inc   (NASDAQ: CRVO)
 
Price: $2.5300 $-0.04 -1.556%
Day's High: $2.5799999237060547 Week Perf: 0.00
Day's Low: $ 2.49 30 Day Perf: -13.65 %
Volume (M): 111,300 52 Wk High: $ 10.00
Volume (M$): $ 0 52 Wk Avg: $5.15
Open: $2.54 52 Wk Low: $2.13



 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 9
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cervomed Inc is a medical technology company that specializes in developing and manufacturing devices for the treatment of neurological disorders. The company's focus is on designing innovative solutions to improve the quality of life for patients suffering from conditions such as chronic pain, epilepsy, and movement disorders. Cervomed Inc aims to provide safe and effective products that utilize advanced technologies to address these neurological issues.


   Company Address: 20 Park Plaza, Suite 424 Boston 2116 MA
   Company Phone Number: 744-4400   Stock Exchange / Ticker: NASDAQ CRVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -2.74%    
CGTX   -1.94%    
LONA        0.13% 
MDT   -1.02%    
SYK   -7.14%    
ZBH   -2.07%    
• View Complete Report
   



Clinical Study

Advancements in DLB Research CervoMeds Update on Neflamapimod Trials at the 8th International Lewy Body Dementia C...

Published Fri, Jan 31 2025 7:14 PM UTC

Lewy Body Dementia (DLB) represents one of the most challenging neurodegenerative conditions, characterized by cognitive fluctuations, visual hallucinations, and motor symptoms. Efforts to develop effective pharmacological interventions are ongoing, with promising developments in clinical trials. One such advancement comes from CervoMed, which presented updates on its Nefla...
Clinical Study

CervoMed’s Neflamapimod Misses Key Endpoints in Phase 2b Trial for Dementia with Lewy Bodies; Upcoming Presentati...

Published Mon, Dec 30 2024 9:33 AM UTC

CervoMed, a biopharmaceutical company focused on innovative therapies for neurodegenerative diseases, recently announced the topline results from its Phase 2b clinical trial, dubbed RewinD-LB, which investigated the efficacy of nefamapimod in patients diagnosed with dementia with Lewy bodies (DLB). Unfortunately, the findings revealed that nefamapimod did not achieve statist...
Shares

CervoMed Announces Key Senior Leadership Appointments to Propel Neflamapimod Development Amidst Promising Findings

Published Wed, Nov 13 2024 1:00 PM UTC

In an ambitious move to bolster its pioneering efforts in neurodegenerative disease research, CervoMed has announced a series of key senior leadership appointments. These strategic hires, focused on enhancing scientific and regulatory expertise, are meticulously aligned with the company s commitment to advance the development of neflamapimod, a promising therapeutic candidat...
Clinical Study

Pioneering Insights into Neurodegenerative Disease CervoMeds Promising Findings at the CTAD Conference

Published Mon, Nov 4 2024 1:00 PM UTC

In the ever-evolving field of neurodegenerative research, CervoMed Inc. has emerged as a beacon of hope following its recent presentations at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD). The company s findings from the AscenD-LB Phase 2a trial in Dementia with Lewy Bodies (DLB) have shed critical light on potential biomarkers for monitoring disease ac...
Clinical Study

CervoMeds Neflamapimod A Beacon of Hope in Early-Stage Dementia with Lewy Bodies as Phase 2b Trial Concludes,

Published Tue, Oct 15 2024 12:01 PM UTC

Dementia with Lewy bodies (DLB), a progressive neurodegenerative disorder, presents a considerable challenge in the realm of medical research and treatment, primarily due to its complex pathology and overlapping symptoms with Alzheimer s and Parkinson s diseases. As the global population ages, the prevalence of DLB is expected to rise, amplifying the need for innovative trea...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 11.21
Price to Sales (Expected) -
Price to Book 2.21
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.69
Working Capital Ratio 6.65
Leverage Ratio (MRQ) 0.42
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.29 $
Revenues (TTM) 0.23 $
Cash Flow (TTM) -
Cash 1.4 $
Book Value 1.15 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,002,433
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Cervomed Inc Outlook

On May 15 2024 the Cervomed Inc provided following guidance

Cervomed Inc. has recently released its financial results for the first quarter of 2024 and also provided several corporate updates. The company is pleased to announce that it is on track to complete enrollment in the second quarter of 2024 for its RewinD-LB Phase 2b clinical trial, which is evaluating the use of neflamapimod in patients with dementia with Lewy bodies (DLB). The topline data from this trial is expected to be available in the fourth quarter of 2024.

This progress in the clinical trial is a significant milestone for Cervomed Inc., as it marks a key step forward in the development of a potential treatment for patients suffering from DLB. The company is dedicated to advancing research in ...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.